Sargent Bickham Lagudis’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Sargent Bickham Lagudis’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-350	Closed	-$7K	–	804
2017 Q4	$7K	Hold	350	–	–	﹤0.01%	657
2017 Q3	$6K	Hold	350	–	–	﹤0.01%	683
2017 Q2	$12K	Hold	350	–	–	﹤0.01%	552
2017 Q1	$11K	Hold	350	–	–	﹤0.01%	581
2016 Q4	$13K	Sell	350 -202	-37%	-$8.06K	﹤0.01%	529
2016 Q3	$25K	Sell	552 -448	-45%	-$23.4K	﹤0.01%	451
2016 Q2	$40K	Hold	1,000	–	–	0.01%	371
2016 Q1	$40K	Buy	+1,000	New	+$58.7K	0.01%	397

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sargent Bickham Lagudis's TEVA Position: Q1 2018 in Review

Sargent Bickham Lagudis sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2018, closing a stake of 350 shares — an estimated $7K sold.

Sargent Bickham Lagudis first reported a position in TEVA in Q1 2016 and held it in 8 quarters. The position peaked at $40K in Q2 2016. 507 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

Sargent Bickham Lagudis reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2018 after selling out during the quarter.
Sargent Bickham Lagudis sold 350 Teva Pharmaceutical Industries Limited shares in Q1 2018, an estimated $7K.
Sargent Bickham Lagudis first reported a position in Teva Pharmaceutical Industries Limited in Q1 2016 and held it in 8 quarters.
Sargent Bickham Lagudis's Teva Pharmaceutical Industries Limited position peaked at $40K in Q2 2016.
507 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2018.

Based on Sargent Bickham Lagudis's 13F filing for Q1 2018, filed 13 Sep 2021.